A consistent skincare routine isn’t just about looking good—it’s about keeping your skin healthy for the long run. The ...

- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne - - Over 30 million acne patients seek ...

Perioral dermatitis is a common inflammatory skin disease presenting as tiny papules or pustules localized around the mouth, nose, or eyes. It is often confused with acne vulgaris, rosacea, and ...

Dermata Therapeutics, Inc. ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive ...

- XYNGARI achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI is the first once-weekly topical product ...

Journey Medical Corporation has announced the launch and initial distribution of Emrosi™, a new prescription medication designed to treat inflammatory lesions of rosacea in adults. Emrosi, which ...

A new era opens for paper. And starts fromhydrolyzed celluloseobtained through enzymatic hydrolysis processes, and which has ...

- XYNGARI™ is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 clinical trial for moderate-to-severe acne- - Over 30 million acne patients seek treatment in ...

There are many possible causes for red, hot cheeks in adults, commonly known as facial flushing. Physiologically, it occurs when blood vessels just below the surface of the skin, called capillaries, ...